BioCentury
ARTICLE | Clinical News

Lipomel: Began Phase II trial

April 24, 2000 7:00 AM UTC

Biovector Therapeutics S.A., Toulouse, France Product: Lipomel Business: Cancer Therapeutic category: Immune stimulation Target: Immune cells Description: Therapeutic vaccine using the MART melanoma ...